Citius Pharmaceuticals reports positive early stage results of cancer combo treatment
seekingalpha
2024-11-11
Citius Pharmaceuticals (NASDAQ:CTXR) and its subsidiary Citius Oncology (NASDAQ:CTOR) have reported positive early-stage results from an investigator-initiated clinical trial evaluating a combined regimen of LYMPHIR (denileukin diftitox-cxdl or E7777) and Keytruda (pembrolizumab), Merck’s (NYSE:MRK) blockbuster